Cardiometabolic Management in Type 2 Diabetes
Summary
Type 2 diabetes presents a dual challenge of dysregulated glucose metabolism and elevated cardiovascular risk. Effective cardiometabolic management integrates lifestyle modification, glycaemic control and targeted therapies to mitigate both microvascular and macrovascular complications. Beyond standard metformin therapy, recent guidelines have prioritised agents with proven cardiovascular benefit, notably sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. Multifactorial interventions now encompass blood pressure optimisation, lipid management and renal protection, reflecting an understanding that cardiovascular outcomes are closely tied to glycaemic trajectories, weight status and renal function. Personalised treatment algorithms account for patient comorbidities, cardiovascular history and risk profiles, with an emphasis on early adoption of cardio-protective therapies. Technological advances in continuous glucose monitoring and telemedicine have further refined treatment paradigms, enabling real-time risk stratification and adherence support. Globally, implementation of these approaches has varied, revealing persistent gaps in access and prescribing patterns. Current research thus focuses on overcoming clinical inertia, standardising best-practice implementation and extending benefits to underserved populations.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Cardiometabolic Management in Type 2 Diabetes publication trend
The graph below shows the total number of articles in cardiometabolic management in type 2 diabetes across all publications each year (not limited to Nature Index journals).
Technical terms
HbA1c: Glycosylated haemoglobin reflecting average blood glucose over the preceding three months.
Sodium–glucose co-transporter 2 inhibitor (SGLT-2 inhibitor): Oral agent that reduces renal glucose reabsorption, improving glycaemic control and lowering cardiovascular risk.
Glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist): Injectable or oral therapy mimicking incretin hormone action to enhance insulin secretion and confer cardiovascular protection.
Cardiometabolic risk: Combined likelihood of cardiovascular and metabolic complications in individuals with diabetes.
eGFR: Estimated glomerular filtration rate, a measure of kidney function based on serum creatinine, age, sex and ethnicity.
References
- The Impact of Web-Based Continuing Medical Education Using Patient Simulation on Real-World Treatment Selection in Type 2 Diabetes: Retrospective Case-Control Analysis. JMIR Medical Education (2023).
- Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data. The BMJ (2024).
- Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER. BMC Endocrine Disorders (2022).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.